Literature DB >> 33791045

The Age-AST-D Dimer (AAD) Regression Model Predicts Severe COVID-19 Disease.

Fátima Higuera-de-la-Tijera1,2, Alfredo Servín-Caamaño1,3, Daniel Reyes-Herrera1,3, Argelia Flores-López1,3, Enrique J A Robiou-Vivero1,3, Felipe Martínez-Rivera1,3, Victor Galindo-Hernández1,3, Victor H Rosales-Salyano1,3, Catalina Casillas-Suárez1,4, Oscar Chapa-Azuela1,5, Alfonso Chávez-Morales1,6, Billy Jiménez-Bobadilla1,7, María L Hernández-Medel1,8, Benjamín Orozco-Zúñiga1,9, Jed R Zacarías-Ezzat1,5, Santiago Camacho1,2, José L Pérez-Hernández1,2.   

Abstract

AIM: Coronavirus disease (COVID-19) ranges from mild clinical phenotypes to life-threatening conditions like severe acute respiratory syndrome (SARS). It has been suggested that early liver injury in these patients could be a risk factor for poor outcome. We aimed to identify early biochemical predictive factors related to severe disease development with intensive care requirements in patients with COVID-19.
METHODS: Data from COVID-19 patients were collected at admission time to our hospital. Differential biochemical factors were identified between seriously ill patients requiring intensive care unit (ICU) admission (ICU patients) versus stable patients without the need for ICU admission (non-ICU patients). Multiple linear regression was applied, then a predictive model of severity called Age-AST-D dimer (AAD) was constructed (n = 166) and validated (n = 170).
RESULTS: Derivation cohort: from 166 patients included, there were 27 (16.3%) ICU patients that showed higher levels of liver injury markers (P < 0.01) compared with non-ICU patients: alanine aminotrasnferase (ALT) 225.4 ± 341.2 vs. 41.3 ± 41.1, aspartate aminotransferase (AST) 325.3 ± 382.4 vs. 52.8 ± 47.1, lactic dehydrogenase (LDH) 764.6 ± 401.9 vs. 461.0 ± 185.6, D-dimer (DD) 7765 ± 9109 vs. 1871 ± 4146, and age 58.6 ± 12.7 vs. 49.1 ± 12.8. With these finding, a model called Age-AST-DD (AAD), with a cut-point of <2.75 (sensitivity = 0.797 and specificity = 0.391, c - statistic = 0.74; 95%IC: 0.62-0.86, P < 0.001), to predict the risk of need admission to ICU (OR = 5.8; 95% CI: 2.2-15.4, P = 0.001), was constructed. Validation cohort: in 170 different patients, the AAD model < 2.75 (c - statistic = 0.80 (95% CI: 0.70-0.91, P < 0.001) adequately predicted the risk (OR = 8.8, 95% CI: 3.4-22.6, P < 0.001) to be admitted in the ICU (27 patients, 15.95%).
CONCLUSIONS: The elevation of AST (a possible marker of early liver injury) along with DD and age efficiently predict early (at admission time) probability of ICU admission during the clinical course of COVID-19. The AAD model can improve the comprehensive management of COVID-19 patients, and it could be useful as a triage tool to early classify patients with a high risk of developing a severe clinical course of the disease.
Copyright © 2021 Fátima Higuera-de-la-Tijera et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33791045      PMCID: PMC7996042          DOI: 10.1155/2021/6658270

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  27 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  COVID-19 in a designated infectious diseases hospital outside Hubei Province, China.

Authors:  Qingxian Cai; Deliang Huang; Pengcheng Ou; Hong Yu; Zhibin Zhu; Zhang Xia; Yinan Su; Zhenghua Ma; Yiming Zhang; Zhiwei Li; Qing He; Lei Liu; Yang Fu; Jun Chen
Journal:  Allergy       Date:  2020-04-17       Impact factor: 13.146

3.  Clinical characteristics of 82 cases of death from COVID-19.

Authors:  Bicheng Zhang; Xiaoyang Zhou; Yanru Qiu; Yuxiao Song; Fan Feng; Jia Feng; Qibin Song; Qingzhu Jia; Jun Wang
Journal:  PLoS One       Date:  2020-07-09       Impact factor: 3.240

4.  COVID-19 in the USA: a question of time.

Authors: 
Journal:  Lancet       Date:  2020-04-18       Impact factor: 79.321

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

Review 6.  Immunology of COVID-19: Current State of the Science.

Authors:  Nicolas Vabret; Graham J Britton; Conor Gruber; Samarth Hegde; Joel Kim; Maria Kuksin; Rachel Levantovsky; Louise Malle; Alvaro Moreira; Matthew D Park; Luisanna Pia; Emma Risson; Miriam Saffern; Bérengère Salomé; Myvizhi Esai Selvan; Matthew P Spindler; Jessica Tan; Verena van der Heide; Jill K Gregory; Konstantina Alexandropoulos; Nina Bhardwaj; Brian D Brown; Benjamin Greenbaum; Zeynep H Gümüş; Dirk Homann; Amir Horowitz; Alice O Kamphorst; Maria A Curotto de Lafaille; Saurabh Mehandru; Miriam Merad; Robert M Samstein
Journal:  Immunity       Date:  2020-05-06       Impact factor: 31.745

7.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

Review 8.  COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.

Authors:  Wolfgang Miesbach; Michael Makris
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

Review 9.  Coagulopathy in COVID-19.

Authors:  Toshiaki Iba; Jerrold H Levy; Marcel Levi; Jecko Thachil
Journal:  J Thromb Haemost       Date:  2020-07-21       Impact factor: 16.036

10.  COVID-19 and its implications for thrombosis and anticoagulation.

Authors:  Jean M Connors; Jerrold H Levy
Journal:  Blood       Date:  2020-06-04       Impact factor: 25.476

View more
  2 in total

1.  Statistical Analysis and Machine Learning Prediction of Disease Outcomes for COVID-19 and Pneumonia Patients.

Authors:  Yu Zhao; Rusen Zhang; Yi Zhong; Jingjing Wang; Zuquan Weng; Heng Luo; Cunrong Chen
Journal:  Front Cell Infect Microbiol       Date:  2022-04-19       Impact factor: 6.073

Review 2.  Association of Prognostic Nutritional Index with Severity and Mortality of Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Kuo-Chuan Hung; Ching-Chung Ko; Li-Kai Wang; Ping-Hsin Liu; I-Wen Chen; Yen-Ta Huang; Cheuk-Kwan Sun
Journal:  Diagnostics (Basel)       Date:  2022-06-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.